Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul;24(7):181-189.
doi: 10.1007/s11910-024-01341-2. Epub 2024 May 23.

Blood Pressure Management in Intracerebral Haemorrhage: when, how much, and for how long?

Affiliations
Review

Blood Pressure Management in Intracerebral Haemorrhage: when, how much, and for how long?

Chloe A Mutimer et al. Curr Neurol Neurosci Rep. 2024 Jul.

Abstract

Purpose of review: When compared to ischaemic stroke, there have been limited advances in acute management of intracerebral haemorrhage. Blood pressure control in the acute period is an intervention commonly implemented and recommended in guidelines, as elevated systolic blood pressure is common and associated with haematoma expansion, poor functional outcomes, and mortality. This review addresses the uncertainty around the optimal blood pressure intervention, specifically timing and length of intervention, intensity of blood pressure reduction and agent used.

Recent findings: Recent pivotal trials have shown that acute blood pressure intervention, to a systolic target of 140mmHg, does appear to be beneficial in ICH, particularly when bundled with other therapies such as neurosurgery in selected cases, access to critical care units, blood glucose control, temperature management and reversal of coagulopathy. Systolic blood pressure should be lowered acutely in intracerebral haemorrhage to a target of approximately 140mmHg, and that this intervention is generally safe in the ICH population.

Keywords: Antihypertensive Agents; Hypertension; Intracerebral Haemorrhage; Patient care Bundles.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Greenberg SM, Ziai WC, Cordonnier C, Dowlatshahi D, Francis B, Goldstein JN, et al. 2022 Guideline for the management of patients with spontaneous intracerebral hemorrhage: a Guideline from the American Heart Association/American Stroke Association. Stroke. 2022;53(7):e282–361. doi: 10.1161/STR.0000000000000407. - DOI - PubMed
    1. Mayer SA. Ultra-early hemostatic therapy for intracerebral hemorrhage. Stroke. 2003;34(1):224–9. doi: 10.1161/01.str.0000046458.67968.e4. - DOI - PubMed
    1. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al. Efficacy and safety of recombinant activated factor VII for Acute Intracerebral Hemorrhage. N Engl J Med. 2008;358(20):2127–37. doi: 10.1056/NEJMoa0707534. - DOI - PubMed
    1. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al. Recombinant activated factor VII for Acute Intracerebral Hemorrhage. N Engl J Med. 2005;352(8):777–85. doi: 10.1056/NEJMoa042991. - DOI - PubMed
    1. Meretoja A, Yassi N, Wu TY, Churilov L, Sibolt G, Jeng JS, et al. Tranexamic acid in patients with intracerebral haemorrhage (STOP-AUST): a multicentre, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2020;19(12):980–7. doi: 10.1016/s1474-4422(20)30369-0. - DOI - PubMed

MeSH terms

Substances